Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
CA 2220458 C · Owner: Mckenzie, Ann T. · Inventors: Mckenzie, Ann T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel crystalline form of R-(R*,R*)-2-(4-fluorophenyl)-.beta..delta.dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl-1H-pyrrole-1heptanoic acid hemi calcium salt designated Form III is characterized by its Xray powder diffraction and/or solid state NMR is described as well as methods , for the preparation and pharmaceutical composition of the same which is , useful as an agent for treating hyperlipidemia and hypercholesterolemia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 8, 1996 and granted September 24, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 8, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 8, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.